<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643952</url>
  </required_header>
  <id_info>
    <org_study_id>3009-029</org_study_id>
    <secondary_id>MK-3009-029</secondary_id>
    <secondary_id>184155</secondary_id>
    <nct_id>NCT03643952</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)</brief_title>
  <official_title>A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years With Complicated Skin and Soft Tissue Infections or Bacteremia Caused by Gram-positive Cocci</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, efficacy and pharmacokinetic (PK)&#xD;
      parameters of daptomycin for injection in Japanese pediatric participants aged 1 to 17 years&#xD;
      with complicated skin and soft tissue infection (cSSTI) or bacteremia caused by gram-positive&#xD;
      cocci.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Actual">April 7, 2020</completion_date>
  <primary_completion_date type="Actual">April 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an Adverse Event</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants That Discontinued Study Treatment Due to an Adverse Event (AE)</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Who Experienced Clinical Success</measure>
    <time_frame>Up to 7 days following end of treatment (up to 49 days)</time_frame>
    <description>Clinical success in participants with MRSA infections was defined as either &quot;Cure&quot; - Resolution of clinically significant signs and symptoms associated with admission infection and no further antibiotic therapy required, OR &quot;Improved&quot;- partial resolution of clinical signs or symptoms of infection with no further antibiotic therapy required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With MRSA Infections Who Experienced a Microbiological Response</measure>
    <time_frame>Up to 7 days following end of treatment (up to 49 days)</time_frame>
    <description>Participant-level microbiological response in participants with MRSA infections at baseline is defined as absence or presumed absence of all baseline infecting pathogens AND no gram-positive superinfection or gram-positive new infection, as assessed by infection site specimen culture or blood culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24hr) of Daptomycin</measure>
    <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
    <description>Blood samples were collected at pre-specified time points to determine the AUC0-24 of daptomycin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Daptomycin</measure>
    <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
    <description>Blood samples were collected at pre-specified timepoints to determine Cmax of daptomycin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Daptomycin</measure>
    <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
    <description>Blood samples were collected at pre-specified time points to determine Tmax of daptomycin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight Adjusted Clearance (CLss/wt) of Daptomycin</measure>
    <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
    <description>Blood samples were collected at pre-specified time points to determine CLss/wt of daptomycin at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Daptomycin</measure>
    <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
    <description>Blood samples were collected at pre-specified time points to determine Vss (mL) of daptomycin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life (t½) of Daptomycin</measure>
    <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
    <description>Blood samples were collected at pre-specified time points to determine the t½ of daptomycin.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Bacteremia</condition>
  <condition>Soft Tissue Infections</condition>
  <condition>Skin Diseases, Infectious</condition>
  <arm_group>
    <arm_group_label>Daptomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin for Injection</intervention_name>
    <description>Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.</description>
    <arm_group_label>Daptomycin</arm_group_label>
    <other_name>MK-3009</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Requires treatment for cSSTI or bacteremia.&#xD;
&#xD;
          -  Is male or female Japanese aged ≥ 1 to ≤ 17 years on the day of signing informed&#xD;
             consent.&#xD;
&#xD;
          -  As a male participant, has agreed to use contraception during the treatment period and&#xD;
             for at least 14 days after the last dose of study treatment and refrain from donating&#xD;
             sperm during this period.&#xD;
&#xD;
          -  As a female participant, has agreed to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least one of the following conditions applies: not a woman of&#xD;
             childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive&#xD;
             guidance during the treatment period and for at least 14 days after the last dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  Has agreed to allow any bacterial isolates obtained from protocol-required specimens&#xD;
             related to the current infection to be provided the Central Microbiology Reference&#xD;
             Laboratory for study-related microbiological testing, long-term storage, and other&#xD;
             future testing.&#xD;
&#xD;
        cSSTI Participants&#xD;
&#xD;
          -  Has cSSTI known or suspected to be caused by gram-positive cocci that requires&#xD;
             intravenous antibiotic treatment and diagnosed with either Gram stain or culture.&#xD;
&#xD;
          -  Has at least 3 of the following clinical signs and symptoms associated with the cSSTI:&#xD;
             pain, tenderness to palpation, temperature &gt;37.0°C axillary or &gt;37.5°C oral or &gt;38.0°&#xD;
             C rectal, forehead, or aural, white blood count (WBC) &gt;12,000/mm^3 or ≥10% bands,&#xD;
             swelling and/or induration, erythema (&gt;1 cm beyond edge of wound or abscess), pus&#xD;
             formation, CRP &gt; upper limited of normal.&#xD;
&#xD;
        Bacteremia Participants&#xD;
&#xD;
          -  Have proven bacteremia with pathogen identification of gram-positive cocci at least&#xD;
             one blood culture bottle by conventional culture methods or by a rapid diagnostic test&#xD;
             in screening period.&#xD;
&#xD;
          -  Have probable bacteremia with a blood culture result demonstrating gram-positive cocci&#xD;
             by Gram stain in screening period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has received previous systemic antimicrobial therapy that is effective against&#xD;
             gram-positive cocci and exceeding 72 hours duration administered at any time during&#xD;
             the 96 hours prior to the first dose of study drug.&#xD;
&#xD;
          -  Has a known infection caused solely by gram-negative pathogen(s), fungus(i) or&#xD;
             virus(es).&#xD;
&#xD;
          -  Has pneumonia (septic emboli in the lung is not an exclusion if clear evidence of&#xD;
             source of infection is other than lungs), empyema, meningitis, endocarditis, or&#xD;
             osteoarticular infection.&#xD;
&#xD;
          -  Has a history of or current rhabdomyolysis.&#xD;
&#xD;
          -  Is anticipated to require non-study systemic antibiotics that may be potentially&#xD;
             effective against gram-positive pathogen(s).&#xD;
&#xD;
          -  Has shock or hypotension unresponsive to fluids or vasopressors for ≥ 4 hours.&#xD;
&#xD;
          -  Has significant allergy/hypersensitivity or intolerance to daptomycin.&#xD;
&#xD;
          -  Has renal insufficiency.&#xD;
&#xD;
          -  Has a history of clinically significant (as assessed by the Investigator) muscular&#xD;
             disease, nervous system or seizure disorder, including unexplained muscular weakness,&#xD;
             history of peripheral neuropathy, Guillain-Barre or spinal cord injury; previous&#xD;
             uncomplicated febrile seizure allowed.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, lab abnormality or other&#xD;
             circumstance that might expose the participant to risk by participating in the trial,&#xD;
             confound the results of the trial, or interfere with the participant's participation&#xD;
             for the full duration of the trial.&#xD;
&#xD;
          -  Is a female who is pregnant or is expecting to conceive (or is a male partner of a&#xD;
             female who is expecting to conceive), is breastfeeding, or plans to breastfeed prior&#xD;
             to completion of the study.&#xD;
&#xD;
          -  Is currently participating in, or has participated in, any other clinical study&#xD;
             involving the administration of investigational or experimental medication (not&#xD;
             licensed by regulatory agencies) at the time of the presentation or during the&#xD;
             previous 30 days prior to screening or is anticipated to participate in such a&#xD;
             clinical study during the course of this trial.&#xD;
&#xD;
          -  Has previously participated in this study at any time.&#xD;
&#xD;
          -  Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or&#xD;
             child) who is investigational site or sponsor staff directly involved with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan Community Health Care Organization Chukyo Hospital ( Site 0030)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health care Organization Kyushu Hospital ( Site 0016)</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>806-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maebashi Red Cross Hospital ( Site 0012)</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital ( Site 0015)</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shikoku Medical Center for Children and Adults ( Site 0027)</name>
      <address>
        <city>Zentsuji</city>
        <state>Kagawa</state>
        <zip>765-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Fujigaoka Hospital ( Site 0023)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center ( Site 0025)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization National Mie Hospital ( Site 0002)</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-0125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Beppu Medical Center ( Site 0003)</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <zip>874-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Children's Medical Center ( Site 0004)</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <zip>183-8561</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital ( Site 0005)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba Children's Hospital ( Site 0024)</name>
      <address>
        <city>Chiba</city>
        <zip>266-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kumamoto Medical Center ( Site 0018)</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital ( Site 0020)</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama City Hospital ( Site 0008)</name>
      <address>
        <city>Saitama</city>
        <zip>336-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital ( Site 0029)</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <results_first_submitted>March 3, 2021</results_first_submitted>
  <results_first_submitted_qc>March 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2021</results_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methicillin-resistant S. aureus (MRSA) infections</keyword>
  <keyword>complicated skin and soft tissue infections (cSSTI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Soft Tissue Infections</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03643952/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Daptomycin</title>
          <description>Participants aged 1 to 17 years old with complicated skin and soft tissue infections (cSSTI) or bacteremia received daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daptomycin</title>
          <description>Participants aged 1 to 17 years old with cSSTI or bacteremia received daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Newborns (0-27 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infants and toddlers (28 days-23 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Children (2-11 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adolescents (12-17 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adults (18-64 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From 65-84 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>85 years and over</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Adverse Event</title>
        <description>An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
        <time_frame>Up to 56 days</time_frame>
        <population>All enrolled participants who received at least one dose of daptomycin</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>Participants aged 1 to 17 years old with cSSTI or bacteremia received daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Adverse Event</title>
          <description>An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
          <population>All enrolled participants who received at least one dose of daptomycin</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Discontinued Study Treatment Due to an Adverse Event (AE)</title>
        <description>An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
        <time_frame>Up to 42 days</time_frame>
        <population>All enrolled participants who received at least one dose of daptomycin</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin</title>
            <description>Participants aged 1 to 17 years old with cSSTI or bacteremia received daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Discontinued Study Treatment Due to an Adverse Event (AE)</title>
          <description>An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.</description>
          <population>All enrolled participants who received at least one dose of daptomycin</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Who Experienced Clinical Success</title>
        <description>Clinical success in participants with MRSA infections was defined as either &quot;Cure&quot; - Resolution of clinically significant signs and symptoms associated with admission infection and no further antibiotic therapy required, OR &quot;Improved&quot;- partial resolution of clinical signs or symptoms of infection with no further antibiotic therapy required.</description>
        <time_frame>Up to 7 days following end of treatment (up to 49 days)</time_frame>
        <population>All enrolled participants with cSSTI or bacteremia who had a positive culture of MRSA at baseline and received at least one dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin (MRSA With cSSTI)</title>
            <description>Participants aged 1 to 17 years old with cSSTI and a positive culture of MRSA at baseline received daptomycin intravenously every 24 hours for 5-14 days.</description>
          </group>
          <group group_id="O2">
            <title>Daptomycin (MRSA With Bacteremia)</title>
            <description>Participants aged 1 to 17 years old with bacteremia and a positive culture of MRSA at baseline received daptomycin intravenously every 24 hours for 5-42 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Who Experienced Clinical Success</title>
          <description>Clinical success in participants with MRSA infections was defined as either &quot;Cure&quot; - Resolution of clinically significant signs and symptoms associated with admission infection and no further antibiotic therapy required, OR &quot;Improved&quot;- partial resolution of clinical signs or symptoms of infection with no further antibiotic therapy required.</description>
          <population>All enrolled participants with cSSTI or bacteremia who had a positive culture of MRSA at baseline and received at least one dose of study treatment</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O2" value="100" lower_limit="2.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With MRSA Infections Who Experienced a Microbiological Response</title>
        <description>Participant-level microbiological response in participants with MRSA infections at baseline is defined as absence or presumed absence of all baseline infecting pathogens AND no gram-positive superinfection or gram-positive new infection, as assessed by infection site specimen culture or blood culture.</description>
        <time_frame>Up to 7 days following end of treatment (up to 49 days)</time_frame>
        <population>All enrolled participants with cSSTI or bacteremia who had a positive culture of MRSA at baseline and received at least one dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin (MRSA With cSSTI)</title>
            <description>Participants aged 1 to 17 years old with cSSTI and a positive culture of MRSA at baseline received daptomycin intravenously every 24 hours for 5-14 days</description>
          </group>
          <group group_id="O2">
            <title>Daptomycin (MRSA With Bacteremia)</title>
            <description>Participants aged 1 to 17 years old with bacteremia and a positive culture of MRSA at baseline received daptomycin intravenously every 24 hours for 5-42 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With MRSA Infections Who Experienced a Microbiological Response</title>
          <description>Participant-level microbiological response in participants with MRSA infections at baseline is defined as absence or presumed absence of all baseline infecting pathogens AND no gram-positive superinfection or gram-positive new infection, as assessed by infection site specimen culture or blood culture.</description>
          <population>All enrolled participants with cSSTI or bacteremia who had a positive culture of MRSA at baseline and received at least one dose of study treatment</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="29.0" upper_limit="96.3"/>
                    <measurement group_id="O2" value="100" lower_limit="2.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24hr) of Daptomycin</title>
        <description>Blood samples were collected at pre-specified time points to determine the AUC0-24 of daptomycin.</description>
        <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
        <population>All enrolled participants who received at least 3 consecutive intravenous (IV) infusions of study treatment, had at least 1 pharmacokinetic (PK) sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin (cSSTI)</title>
            <description>Participants with cSSTI received daptomycin intravenously every 24 hours for 5-14 days.</description>
          </group>
          <group group_id="O2">
            <title>Daptomycin (Bacteremia)</title>
            <description>Participants with bacteremia received daptomycin intravenously every 24 hours for 5-42 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24hr) of Daptomycin</title>
          <description>Blood samples were collected at pre-specified time points to determine the AUC0-24 of daptomycin.</description>
          <population>All enrolled participants who received at least 3 consecutive intravenous (IV) infusions of study treatment, had at least 1 pharmacokinetic (PK) sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
          <units>µg·hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age Category 1-&lt;2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="574" spread="99.1"/>
                    <measurement group_id="O2" value="502" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 2-6 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431" spread="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 7-11 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409" spread="143"/>
                    <measurement group_id="O2" value="599" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 12-17 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316" spread="18.2"/>
                    <measurement group_id="O2" value="422" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of Daptomycin</title>
        <description>Blood samples were collected at pre-specified timepoints to determine Cmax of daptomycin.</description>
        <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
        <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin (cSSTI)</title>
            <description>Participants diagnosed with cSSTI received daptomycin intravenously every 24 hours for 5-14 days.</description>
          </group>
          <group group_id="O2">
            <title>Daptomycin (Bacteremia)</title>
            <description>Participants with bacteremia received daptomycin intravenously every 24 hours for 5-42 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Daptomycin</title>
          <description>Blood samples were collected at pre-specified timepoints to determine Cmax of daptomycin.</description>
          <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age Category 1-&lt;2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" spread="6.66"/>
                    <measurement group_id="O2" value="104" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 2-6 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 7-11 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" spread="15.1"/>
                    <measurement group_id="O2" value="73.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 12-17 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="1.33"/>
                    <measurement group_id="O2" value="94.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Daptomycin</title>
        <description>Blood samples were collected at pre-specified time points to determine Tmax of daptomycin</description>
        <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
        <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin (cSSTI)</title>
            <description>Participants with cSSTI received daptomycin intravenously every 24 hours for 5-14 days.</description>
          </group>
          <group group_id="O2">
            <title>Daptomycin (Bacteremia)</title>
            <description>Participants with bacteremia received daptomycin intravenously every 24 hours for 5-42 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of Daptomycin</title>
          <description>Blood samples were collected at pre-specified time points to determine Tmax of daptomycin</description>
          <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age Category 1-&lt;2 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.33" upper_limit="1.37"/>
                    <measurement group_id="O2" value="1.27" lower_limit="1.20" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 2-6 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="1.12" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 7-11 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.833" lower_limit="0.783" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.800" lower_limit="0.800" upper_limit="0.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 12-17 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" lower_limit="0.750" upper_limit="0.750"/>
                    <measurement group_id="O2" value="0.733" lower_limit="0.733" upper_limit="0.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Adjusted Clearance (CLss/wt) of Daptomycin</title>
        <description>Blood samples were collected at pre-specified time points to determine CLss/wt of daptomycin at steady state.</description>
        <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
        <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin (cSSTI)</title>
            <description>Participants with cSSTI received daptomycin intravenously every 24 hours for 5-14 days.</description>
          </group>
          <group group_id="O2">
            <title>Daptomycin (Bacteremia)</title>
            <description>Participants with bacteremia received daptomycin intravenously every 24 hours for 5-42 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight Adjusted Clearance (CLss/wt) of Daptomycin</title>
          <description>Blood samples were collected at pre-specified time points to determine CLss/wt of daptomycin at steady state.</description>
          <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
          <units>mL/hr/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age Category 1-&lt;2 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="2.86"/>
                    <measurement group_id="O2" value="23.9" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 2-6 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 7-11 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="8.27"/>
                    <measurement group_id="O2" value="15.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 12-17 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="0.917"/>
                    <measurement group_id="O2" value="16.6" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss) of Daptomycin</title>
        <description>Blood samples were collected at pre-specified time points to determine Vss (mL) of daptomycin.</description>
        <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
        <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin (cSSTI)</title>
            <description>Participants with cSSTI received daptomycin intravenously every 24 hours for 5-14 days.</description>
          </group>
          <group group_id="O2">
            <title>Daptomycin (Bacteremia)</title>
            <description>Participants with bacteremia received daptomycin intravenously every 24 hours for 5-42 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) of Daptomycin</title>
          <description>Blood samples were collected at pre-specified time points to determine Vss (mL) of daptomycin.</description>
          <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age Category 1-&lt;2 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1146" spread="299"/>
                    <measurement group_id="O2" value="1918" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 2-6 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1753" spread="486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 7-11 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3929" spread="2032"/>
                    <measurement group_id="O2" value="4013" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 12-17 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6414" spread="1086"/>
                    <measurement group_id="O2" value="5106" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-Life (t½) of Daptomycin</title>
        <description>Blood samples were collected at pre-specified time points to determine the t½ of daptomycin.</description>
        <time_frame>Pre-dose and at 15 minutes, 1 hour, 4 hours, and 12 hours post-dose on Day 3 of daptomycin treatment</time_frame>
        <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin (cSSTI)</title>
            <description>Participants with cSSTI received daptomycin intravenously every 24 hours for 5-14 days.</description>
          </group>
          <group group_id="O2">
            <title>Daptomycin (Bacterermia)</title>
            <description>Participants with bacteremia received daptomycin intravenously every 24 hours for 5-42 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-Life (t½) of Daptomycin</title>
          <description>Blood samples were collected at pre-specified time points to determine the t½ of daptomycin.</description>
          <population>All enrolled participants who received at least 3 consecutive IV infusions of study treatment, had at least 1 PK sample following study drug administration, and did not have any protocol violations affecting the PK profile</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age Category 1-&lt;2 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="0.460"/>
                    <measurement group_id="O2" value="4.46" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 2-6 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="0.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 7-11 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="1.09"/>
                    <measurement group_id="O2" value="5.85" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age Category 12-17 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="0.942"/>
                    <measurement group_id="O2" value="3.98" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 56 days</time_frame>
      <desc>All enrolled participants who received at least one dose of daptomycin</desc>
      <group_list>
        <group group_id="E1">
          <title>Daptomycin</title>
          <description>Participants aged 1 to 17 years old with cSSTI or bacteremia received daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastrointestinal mucosal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was concluded due to the difficulty of enrolling pediatric patients into the study during the COVID-19 pandemic. This study concluded enrollment with 18 participants, versus the 20 that were originally planned.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

